|
End-of-day quote
Shenzhen S.E.
22/09/2026
|
5-day change | 1st Jan Change | ||
| 5.910 CNY | -0.17% |
|
+6.10% | -19.81% |
| 08-25 | Beijing SL Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026 | CI |
| 06-01 | Beijing SL Pharmaceutical Co., Ltd. Approves Cash Dividend for 2025 | CI |
Company Valuation: Beijing SL Pharmaceutical Co., Ltd.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 10,376 | 11,106 | 8,445 | 10,469 | 7,674 | 7,572 |
| Change | - | 7.03% | -23.96% | 23.97% | -26.69% | -1.34% |
| Enterprise Value (EV) 1 | 8,939 | 9,472 | 6,992 | 8,390 | 5,692 | 6,430 |
| Change | - | 5.96% | -26.19% | 20.01% | -32.16% | 12.97% |
| P/E | 28.1x | 26.4x | 35.7x | 24.9x | -107x | -21.7x |
| PBR | 2.09x | 2.09x | 1.54x | 1.8x | 1.38x | 1.46x |
| PEG | - | 1.9x | -0.8x | 0.3x | 1x | -0x |
| Capitalization / Revenue | 9.32x | 9.14x | 8.04x | 10.3x | 11.6x | 12.1x |
| EV / Revenue | 8.03x | 7.8x | 6.66x | 8.24x | 8.62x | 10.3x |
| EV / EBITDA | 37.3x | 30.3x | 27.2x | 23.5x | 31.5x | 40.4x |
| EV / EBIT | 59.6x | 44.6x | 48.7x | 39.7x | 206x | -838x |
| EV / FCF | 94.3x | 83x | 57.6x | 66.4x | -21.9x | -176x |
| FCF Yield | 1.06% | 1.2% | 1.74% | 1.51% | -4.57% | -0.57% |
| Dividend per Share 2 | 0.1 | 0.1 | 0.1 | 0.15 | 0.02 | 0.01 |
| Rate of return | 0.99% | 0.93% | 1.22% | 1.47% | 0.27% | 0.14% |
| EPS 2 | 0.36 | 0.41 | 0.23 | 0.41 | -0.07 | -0.34 |
| Distribution rate | 27.8% | 24.4% | 43.5% | 36.6% | -28.6% | -2.94% |
| Net sales 1 | 1,113 | 1,215 | 1,050 | 1,018 | 660.4 | 623.6 |
| EBITDA 1 | 239.4 | 312.1 | 257.2 | 356.5 | 180.6 | 159.1 |
| EBIT 1 | 149.9 | 212.5 | 143.7 | 211.1 | 27.65 | -7.676 |
| Net income 1 | 364.7 | 425.9 | 234.4 | 416.7 | -74.07 | -347.2 |
| Net Debt 1 | -1,437 | -1,634 | -1,453 | -2,078 | -1,982 | -1,141 |
| Reference price 2 | 10.100 | 10.810 | 8.220 | 10.190 | 7.470 | 7.370 |
| Nbr of stocks (in thousands) | 1,027,350 | 1,027,350 | 1,027,350 | 1,027,350 | 1,027,350 | 1,027,350 |
| Announcement Date | 26/04/21 | 25/04/22 | 25/04/23 | 23/04/24 | 21/04/25 | 28/04/26 |
1CNY in Million2CNY
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 906M | |
| 33.27x | 12.06x | 24.51x | 0.59% | 1,043B | |
| 29.94x | 6.66x | 18.64x | 2% | 649B | |
| 33.54x | 7.85x | 16.21x | 2.59% | 469B | |
| 19.72x | 4.82x | 11.95x | 2.75% | 355B | |
| 20.01x | 5.21x | 12.94x | 3.07% | 270B | |
| 21.55x | 4.46x | 12.7x | 1.98% | 262B | |
| 26.04x | 6.76x | 12.04x | 2.46% | 222B | |
| -46.18x | 6.71x | 26.22x | 2.16% | 189B | |
| 11.59x | 4.21x | 8.76x | 4.34% | 175B | |
| Average | 16.61x | 6.53x | 16.00x | 2.44% | 363.39B | |
| Weighted average by Cap. | 23.93x | 7.81x | 18.02x | 1.97% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- 002038 Stock
- Valuation Beijing SL Pharmaceutical Co., Ltd.
Select your edition
All financial news and data tailored to specific country editions
